BIOMAT Database Logo BIOMAT Database Logo

Serologically active clinically quiescent systemic lupus erythematosus--predictors of clinical flares. 1994

B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Lupus Clinic, Wellesley Hospital, Toronto, ON, Canada.

OBJECTIVE To identify the frequency of serologic activity in the face of clinical quiescence in a large cohort of patients with systemic lupus erythematosus (SLE) followed prospectively in a single center. METHODS In a prospective cohort study, patients serologically active but clinically quiescent (SACQ) in 3 consecutive clinic visits were analyzed for the development of a clinical flare over the subsequent year and were evaluated for predictive factors for flare before and during their SACQ period. RESULTS Forty-six episodes of SACQ went on to clinical flare within one year while 60 did not. No predictive factors for flare were found either during or before the SACQ period. CONCLUSIONS A significant population of patients with SLE are SACQ and must be followed over time and treated only on the basis of clinical criteria.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence

Related Publications

B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Clinically active serologically quiescent systemic lupus erythematosus.
September 2003, The Journal of rheumatology,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome.
September 2010, The Journal of rheumatology,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features.
February 1979, The American journal of medicine,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
May 2015, The Journal of rheumatology,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares.
May 2007, Expert review of clinical immunology,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Follow-up and management of serologically active clinically quiescent cases in pediatric systemic lupus erythematosus.
January 2021, Reumatologia,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus.
December 2015, The Journal of rheumatology,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus.
December 2006, Arthritis and rheumatism,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period.
April 2012, Arthritis care & research,
B A Walz LeBlanc, and D D Gladman, and M B Urowitz
Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study.
October 2021, Arthritis research & therapy,
Copied contents to your clipboard!